title: 2008 Clinical approach to irritable bowel syndrome.
abstract: Irritable bowel syndrome (IBS), as defined by Rome III diagnostic criteria, affects 10-20% of the general population, with women 20-40 years old accounting for the majority of patients. Although variable and intermittent, IBS symptoms may persist for many years. Repeated referrals for medical consultation and diagnostic studies generate huge healthcare costs. Since there is no evidence that IBS leads to more severe gastrointestinal disorders, in absence of alarm symptoms or signs, an invasive diagnostic algorithm is not indicated. Optimal treatment for IBS still needs to be defined. The clinical approach is based on treatment of the prevalent symptom. When pain predominates, antispasmodics are the first choice. In case of diarrhea, loperamide is useful for reducing bowel frequency. Soluble fiber represents the first option in subjects with IBS and constipation or mixed IBS. Dietary integrators composed of probiotics and serotonin precursors are a promising therapeutic option.
authors.affiliation: Unit of Gastro-epatology, San Giovanni Battista Hospital, Turin, Italy. mastegiano@molinette.piemonte.it
authors.forename: M
authors.initials: M
authors.lastname: Astegiano
authors.forename: R
authors.initials: R
authors.lastname: Pellicano
authors.forename: C
authors.initials: C
authors.lastname: Sguazzini
authors.forename: M
authors.initials: M
authors.lastname: Berrutti
authors.forename: D
authors.initials: D
authors.lastname: Simondi
authors.forename: S
authors.initials: S
authors.lastname: Reggiani
authors.forename: M
authors.initials: M
authors.lastname: Rizzetto
mesh_terms: D015746:Abdominal Pain / Q000188:drug therapy; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use; D003248:Constipation / Q000188:drug therapy; D003967:Diarrhea / Q000188:drug therapy; D004043:Dietary Fiber / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D043183:Irritable Bowel Syndrome / Q000175:diagnosis / Q000188:drug therapy* / Q000628:therapy; D015201:Meta-Analysis as Topic; D010276:Parasympatholytics / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D011613:Psychotherapy; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D012702:Serotonin Antagonists / Q000627:therapeutic use; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000929:Antidepressive Agents, Tricyclic; D004043:Dietary Fiber; D010276:Parasympatholytics; D012702:Serotonin Antagonists; D017366:Serotonin Receptor Agonists; D017367:Selective Serotonin Reuptake Inhibitors